return to news
  1. Can India's Cost Advantage Survive Trump's 200 Percent Pharma Tariff? | Markets Today #265

Business News

Can India's Cost Advantage Survive Trump's 200 Percent Pharma Tariff? | Markets Today #265

SUMMARY

In this episode of Markets Today, we decode why Adani and GMR could soon launch airlines if airport ownership rules change, how India's passenger vehicle sales hit a record despite rising car prices, and whether Trump's proposed 200% pharma tariffs are really a threat to Indian drugmakers, given their cost advantage and growing US manufacturing presence.

πŸ“Œ In this episode of Markets Today β€” Adani and GMR may get to launch their own airlines, car prices keep rising but sales just hit a record, and Trump's 200% pharma tariff plan explained β€” will it actually hurt Indian drug companies?

#1 ✈️ Adani GMR Could Run Airlines Govt may relax 10% stake cap for airport operators. India's aviation = 2-player market. IndiGo crisis showed the risk. But airport owners running airlines = slot conflict of interest. Aircraft shortage adds another hurdle.

#2 πŸš— Car Prices Up. Sales Up. Why? Q1 FY27 PV sales: record 12.7 lakh units, up 26% YoY. SUVs = 68% of all sales. 7-year loans turn β‚Ή30,000 hike into β‚Ή350/month extra. Price hike announcements create urgency to buy. Winners: Mahindra, Maruti, Hyundai, Uno Minda, Sona BLW, Motherson.

#3 πŸ’Š Trump's 200% Pharma Tariff Zero for 2 years, then 100%, then 200%. India supplies 47% of US generic prescriptions. But India's cost advantage is 40-60% β€” survives even with tariffs. Not India-specific. Sun Pharma, Dr Reddy's, Lupin, Cipla already have US manufacturing.

About The Author

Upstox
Upstox News Desk is a team of journalists who passionately cover stock markets, economy, commodities, latest business trends, and personal finance.

Next Story